RxDoctor Payments Data

Mamatha Mohan, MD

Internal Medicine · East Orange, NJNPI 1710016761

Payments from drug & device makers

$7,735in general payments, 2019–2025

Across 294 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$814
  • Bayer$811
  • Amgen$459
  • Merck$392
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,735 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$112,197
Medicare patients
95
Services billed
1,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin178$229,972
KerendiaFinerenone63$59,785
OzempicSemaglutide55$59,008
FarxigaDapagliflozin Propanediol54$58,306
RybelsusSemaglutide32$47,994
JanuviaSitagliptin Phosphate27$40,451
EliquisApixaban30$33,732
MounjaroTirzepatide19$32,566
TrulicityDulaglutide20$27,963
XareltoRivaroxaban24$26,183
VascepaIcosapent Ethyl41$26,076
TradjentaLinagliptin31$25,347
EntrestoSacubitril/Valsartan19$23,314
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$23,294
BrilintaTicagrelor17$16,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$814$255,319209 claims
Novo NordiskOzempic, Rybelsus$1,210$107,00287 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,126$97,994103 claims
Lilly USA, LLCMounjaro, Trulicity$300$60,52839 claims
BayerKerendia$811$59,78563 claims
MerckJanuvia$392$40,45127 claims
PfizerEliquis$59$33,73230 claims
Johnson & JohnsonXarelto$30$26,18324 claims
NovartisEntresto$219$23,31419 claims
GSKBreo Ellipta$302$4,87512 claims
Sanofi-aventis U.S. LLCLantus$14$1,23013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in East Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →